Clinical Trials Browser

INDUSTRY × capmatinib × 1 year × Clear all

Carcinoma, Non-Small-Cell Lung

NCT05110196 2026-04-07

Study of Capmatinib in Indian Patients With MET Exon 14 Skipping Mutation Positive Advanced NSCLC.

Phase 4 Completed

50 enrolled

Thoracic

Bronchial Neoplasms, Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03040973 2026-04-02

Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone

Phase 2 Active not recruiting

29 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04677595 2026-03-31

GeoMETry-C

Phase 2 Completed

36 enrolled 26 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04741789 2026-03-16

Managed Access Programs for INC280, Capmatinib

No longer available

Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03333343 2026-01-16

Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC

Phase 1 Active not recruiting

105 enrolled

Thoracic

EGFR-mutant Non-small Cell Lung Cancer

NCT04926831 2025-10-16

Geometry-N

Phase 2 Terminated

4 enrolled 10 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04575025 2025-09-15

Special Drug Use-results Surveillance of Tabrecta Tablets

Completed

109 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03742349 2025-05-18

Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC).

Phase 1 Terminated

64 enrolled

Breast

Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT04427072 2025-05-16

GeoMETry-III

Phase 3 Terminated

22 enrolled 22 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

Clinical Trials

METalmark

Study of Capmatinib in Indian Patients With MET Exon 14 Skipping Mutation Positive Advanced NSCLC.

Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone

GeoMETry-C

Managed Access Programs for INC280, Capmatinib

Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC

Geometry-N

Special Drug Use-results Surveillance of Tabrecta Tablets

Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC).

GeoMETry-III